[Comment] Thrombopoietin-receptor agonists in children with immune thrombocytopenia
Paediatric immune thrombocytopenia is usually a benign condition that results in spontaneous remission within 6–12 months for most of children. Despite severe thrombocytopenia, clinically significant bleeding events are rare. Thus, a common treatment approach for many children is close observation.1 However, a small proportion of children have severe haemorrhage, develop chronic immune thrombocytopenia, are refractory to first-line therapy, or report low health-related quality of life. For these children, development of novel drugs could bring a substantial benefit.